Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.
Researchers deployed a survey to determine the extent of pain, psychiatric, endocrine, and neurologic comorbidities in patients with chronic or episodic migraine.
For patients with chronic migraine, onabotulinumtoxinA was shown to have a better outcome.
Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.
Acupressure is not a beneficial adjunctive therapy to sodium valproate for the treatment of chronic migraine with aura.
More targeted injection sites may improve efficacy and the overall patient experience in chronic migraine.
The majority of centers follow protocols for administration of onabotulinumtoxinA.
A growing body of research indicates a number of shared features between chronic migraine and temporomandibular disorders.
In chronic migraine and medication overuse, those who frequently relapse into overuse after withdrawal have a worse clinical and psychological profile than patients who relapse less frequently.
During headache, patients with chronic migraine had greater activity in the right anterior hypothalamic region than patients with episodic or no migraine.
The study found a strong link between chronic migraine and psychological symptoms and beliefs that contribute to disability.
Remote electrical stimulation appears to have similar efficacy to standard drug treatments, including triptans.
Patients with chronic migraine and comorbidities incur nearly 2 times the health care costs incurred by patients with migraine alone.
A larger percentage of participants receiving CBT plus amitriptyline reached a 50% reduction in migraine frequency during treatment compared with HE plus amitriptyline.
Recovery time varies depending on which class of medication the patient is overusing.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
A 30% or greater decline in mean monthly moderate-to-severe headache days was met by 45.3 % (n=24) of patients treated with occipital nerve stimulation.
Patients in both groups were satisfied with their care.
Previous analysis showed that treatment reduced chronic migraine frequency.
Participants experienced a reduction in headache days as soon as 3 days post-treatment.
Treatment of chronic, but not episodic migraine with botulinum toxin has been added to the treatment guidelines.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics